OR51E2 and Familial prostate cancer: To determine whether PSGR-derived peptide-specific T cells were able to recognize and kill HLA-A2+, PSGR-expressing prostate cancer cells, we used an HLA-A2 negative PC3 cell line and an HLA-A2 positive LNCaP prostate cancer cell line.